Who is sponsoring NCT03661034?

NCT03661034 is sponsored by Cognito Therapeutics, Inc..

What drugs are being tested in NCT03661034?

Interventions in NCT03661034: GammaSense Stimulation System (non-invasive, non-significant risk).

What condition does NCT03661034 study?

NCT03661034 studies Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline.

Is NCT03661034 still recruiting?

NCT03661034 is currently status unknown. Last updated 24 August 2021.

Last reviewed 2021-08-24 · How we verify

NCT03661034

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

Status unknown NA Last updated 24 August 2021

What this trial tests

NA trial testing GammaSense Stimulation System (non-invasive, non-significant risk) in Alzheimer Disease, Early Onset in 20 participants. Status unknown.

Timeline

31 May 2018

Primary endpoint
1 May 2021

1 March 2022

Quick facts

Lead sponsor	Cognito Therapeutics, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	31 May 2018
Primary completion	1 May 2021
Estimated completion	1 March 2022
Sites	1 location across United States

Drugs / interventions tested

GammaSense Stimulation System (non-invasive, non-significant risk)

Conditions studied

Alzheimer Disease, Early Onset — all drugs for Alzheimer Disease, Early Onset →
Alzheimer Disease — all drugs for Alzheimer Disease →
Alzheimer Dementia — all drugs for Alzheimer Dementia →
Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Cognito Therapeutics, Inc.

Who can join

50 and older, any sex, with Alzheimer Disease, Early Onset or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Etude Study is a multi-center, four-arm prospective dose-adjusting study designed to assess the tolerability, safety and efficacy of non-invasive sensory stimulation for patients with cognitive impairment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease.
Toniolo S, Sen A, Husain M. · · 2020 · cited 74× · PMID 33297460 · DOI 10.3390/ijms21239318
Therapy for Alzheimer's disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. · · 2021 · cited 52× · PMID 33711510 · DOI 10.1016/j.arr.2021.101318
Abstract: Posters: 13th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 2020.
· 2020 · cited 2× · PMID 33169785 · DOI 10.14283/jpad.2020.58

Verify or expand the search:

Other recruiting trials for Alzheimer Disease, Early Onset

Currently open trials in the same condition.

NCT06814730 — A Study to Assess THN391 in Subjects With Alzheimer's Disease · Phase 1 · recruiting
NCT06688968 — Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease · NA · recruiting
NCT06668610 — A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia · NA · recruiting
NCT06268886 — Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Partici · Phase 2 · active not recruiting
NCT05983575 — A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03661034 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cognito Therapeutics, Inc.
Last refreshed: 24 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03661034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing